Stocks & Investing
Stocks and Investing
Stocks and Investing
Tue, August 2, 2022
[ Tue, Aug 02nd 2022
] - WOPRAI
[ Tue, Aug 02nd 2022
] - WOPRAI
[ Tue, Aug 02nd 2022
] - WOPRAI
[ Tue, Aug 02nd 2022
] - WOPRAI
[ Tue, Aug 02nd 2022
] - WOPRAI
[ Tue, Aug 02nd 2022
] - WOPRAI
[ Tue, Aug 02nd 2022
] - WOPRAI
[ Tue, Aug 02nd 2022
] - WOPRAI
[ Tue, Aug 02nd 2022
] - WOPRAI
[ Tue, Aug 02nd 2022
] - WOPRAI
[ Tue, Aug 02nd 2022
] - WOPRAI
[ Tue, Aug 02nd 2022
] - WOPRAI
[ Tue, Aug 02nd 2022
] - WOPRAI
[ Tue, Aug 02nd 2022
] - WOPRAI
[ Tue, Aug 02nd 2022
] - WOPRAI
[ Tue, Aug 02nd 2022
] - WOPRAI
[ Tue, Aug 02nd 2022
] - WOPRAI
[ Tue, Aug 02nd 2022
] - WOPRAI
[ Tue, Aug 02nd 2022
] - WOPRAI
[ Tue, Aug 02nd 2022
] - WOPRAI
[ Tue, Aug 02nd 2022
] - WOPRAI
[ Tue, Aug 02nd 2022
] - WOPRAI
[ Tue, Aug 02nd 2022
] - WOPRAI
[ Tue, Aug 02nd 2022
] - WOPRAI
[ Tue, Aug 02nd 2022
] - WOPRAI
[ Tue, Aug 02nd 2022
] - WOPRAI
[ Tue, Aug 02nd 2022
] - WOPRAI
[ Tue, Aug 02nd 2022
] - WOPRAI
[ Tue, Aug 02nd 2022
] - WOPRAI
Charles Rhyee Downgraded (TDOC) to Hold and Decreased Target to $34 on, Aug 2nd, 2022
Charles Rhyee of Cowen & Co., Downgraded "Teladoc Health, Inc." (TDOC) to Hold and Decreased Target from $58 to $34 on, Aug 2nd, 2022.
Charles has made no other calls on TDOC in the last 4 months.
There are 17 other peers that have a rating on TDOC. Out of the 17 peers that are also analyzing TDOC, 13 agree with Charles's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Cindy Motz of "Goldman Sachs" Downgraded from Strong Buy to Hold and Decreased Target to $36 on, Thursday, July 28th, 2022
- Ryan MacDonald of "Needham" Downgraded from Strong Buy to Hold on, Thursday, July 28th, 2022
- Stephanie Davis Demko of "SVB Leerink" Maintained at Hold with Decreased Target to $34 on, Thursday, July 28th, 2022
- Steve Valiquette of "Barclays" Maintained at Hold with Decreased Target to $40 on, Thursday, July 28th, 2022
- David Grossman of "Stifel" Maintained at Hold with Decreased Target to $36 on, Wednesday, June 29th, 2022
- John Eade of "Argus Research" Downgraded from Strong Buy to Hold on, Thursday, May 5th, 2022
- Jonathan Yong of "Credit Suisse" Downgraded from Buy to Hold and Decreased Target to $35 on, Thursday, April 28th, 2022
- Matt Hewitt of "Craig-Hallum" Maintained at Hold with Decreased Target to $30 on, Thursday, April 28th, 2022
- George Hill of "Deutsche Bank" Maintained at Hold with Decreased Target to $44 on, Thursday, April 28th, 2022
- Daniel Grosslight of "Citigroup" Downgraded from Strong Buy to Hold and Decreased Target to $43 on, Thursday, April 28th, 2022
- Ryan Daniels of "William Blair" Downgraded from Buy to Hold on, Thursday, April 28th, 2022
- Sandy Draper of "Guggenheim" Downgraded from Strong Buy to Hold on, Thursday, April 28th, 2022
- Stan Berenshteyn of "Wells Fargo" Downgraded from Buy to Hold and Held Target at $40 on, Thursday, April 28th, 2022
These are the ratings of the 4 analyists that currently disagree with Charles
- Jessica Tassan of "Piper Sandler" Maintained at Buy with Decreased Target to $40 on, Thursday, July 28th, 2022
- Michael Wiederhorn of "Oppenheimer" Maintained at Buy with Decreased Target to $55 on, Thursday, July 28th, 2022
- Richard Close of "Canaccord Genuity" Maintained at Strong Buy with Decreased Target to $50 on, Thursday, April 28th, 2022
- Sean Dodge of "RBC Capital" Maintained at Buy with Decreased Target to $65 on, Thursday, April 28th, 2022
